PMID: 8947500Nov 15, 1996Paper

Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas

The Biochemical Journal
H J HansenM J Mattes

Abstract

The fate of antibody (Ab) LL1, which reacts with the invariant chain (Ii) subunit of the immature MHC class-II antigen (CD74) after binding to the surface of B-cell lymphomas was investigated. This Ab was internalized and catabolized very rapidly, much faster than other Abs that are considered to be rapidly internalized, such as CD19, CD22 and anti-(transferrin receptor). Such internalization did not depend on Ab cross-linking. The capacity of this uptake process was determined in long-term experiments by increasing the Ab concentration: in 1 day, approx. 8 x 10(5) Ab molecules per cell were catabolized. This analysis was facilitated by the use of radiolabels that are trapped within cells after catabolism of the Abs to which they were conjugated. If the Ab is a reliable marker for the Ii antigen, which is likely, we can conclude that Ii directed to the cell surface appears to be sufficient, indeed more than sufficient, to account for the cell content of mature class-II molecules.

Citations

Dec 9, 2009·Expert Opinion on Investigational Drugs·Zuzana BerkovaFelipe Samaniego
Dec 5, 2008·Expert Opinion on Investigational Drugs·Tomer MarkRuben Niesvizky
May 9, 2008·International Journal of Radiation Biology·M Jules Mattes
Jun 2, 2012·Expert Opinion on Biological Therapy·David M Goldenberg, Robert M Sharkey
May 30, 2008·Advanced Drug Delivery Reviews·Robert M Sharkey, David M Goldenberg
Oct 12, 2014·Journal of Experimental & Clinical Cancer Research : CR·Zuzana BerkovaFelipe Samaniego
Oct 9, 2014·Blood Reviews·Daniel W SherbenouBin Liu
Nov 19, 2013·Drug Discovery Today·Heidi L PerezRobert M Borzilleri
Jan 21, 2015·Endocrine-related Cancer·Shih-Ping ChengJie-Jen Lee
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaSusan O'Brien
Jun 29, 2005·Nuclear Medicine and Biology·Serengulam V GovindanM Jules Mattes
Aug 27, 2014·Pediatric Blood & Cancer·Annelies van Vuren, Friederike Meyer-Wentrup
Mar 21, 2018·Targeted Oncology·Cédric RossiRené-Olivier Casasnovas
Jul 27, 2007·Cancer Biotherapy & Radiopharmaceuticals·Cecilia HindorfGlenn D Flux
May 2, 1997·International Journal of Cancer. Journal International Du Cancer·M J MattesD M Goldenberg
Aug 30, 2014·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy·Laetitia GenèveJacques Thibodeau
May 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Peter J McCormickJuan S Bonifacino
Apr 16, 2010·Physics in Medicine and Biology·C BousisH Nikjoo
Jan 7, 2011·Expert Opinion on Therapeutic Targets·Federica Borghese, Felix I L Clanchy
Jul 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Aura MuntasellDolores Jaraquemada
Jun 11, 1999·International Journal of Cancer. Journal International Du Cancer·G L GriffithsM J Mattes
Jul 21, 2005·Technology in Cancer Research & Treatment·Serengulam V GovindanDavid M Goldenberg
Feb 22, 2012·International Journal of Radiation Biology·Christos BousisHooshang Nikjoo
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rhona SteinDavid M Goldenberg
Feb 22, 2013·Molecular Cancer Therapeutics·Serengulam V GovindanDavid M Goldenberg
Oct 1, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roberta E BurdenChristopher J Scott
Dec 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yicheng MaoNatarajan Muthusamy
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jack D BurtonDavid M Goldenberg
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Puja SapraDavid M Goldenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

© 2021 Meta ULC. All rights reserved